I was just pondering why someone would short a biotech just before some potentially incredible news may come out. Theoretically the risk of this move is off the charts. That would be like shorting Brex at $5 and having it go to $270 before it went to zero. 

In the RVX case there were 2,552,489 units issued last June which consisted of one share and one whole warrant that had a 4 year life. Last week we saw our short interest grow to over 2 million. If a number of these shorters have significant numbers of the outstanding warrants then their risk would be limited to the $2.05 exercise price of those warrants or between .50 and .70 per share. The win on the downside in my view would be significant if something other than "Continue on the way you are" is stated by the DSMB, whenever this  SSRA/FA finally comes out. If this group of shorters does not have warrants to cover then the risk is extreme. I'm pretty sure the company and Bloom Burton Securities Inc know exactly who most of the shorters are.

IMO dyodd

tada